Cargando…

Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapy landscape due to long-term benefits in patients with advanced metastatic disease. However, robust predictive biomarkers for response are still lacking and treatment resistance is not fully understood. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harel, Michal, Lahav, Coren, Jacob, Eyal, Dahan, Nili, Sela, Itamar, Elon, Yehonatan, Raveh Shoval, Shani, Yahalom, Galit, Kamer, Iris, Zer, Alona, Sharon, Ofer, Carbone, David P, Dicker, Adam P, Bar, Jair, Shaked, Yuval
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immunotherapy Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207924/ https://www.ncbi.nlm.nih.gov/pubmed/35718373 http://dx.doi.org/10.1136/jitc-2022-004582

Ejemplares similares

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity
por: Reches, Adi, et al.
Publicado: (2020)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
por: Weppler, Alison M, et al.
Publicado: (2020)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade
por: Vaidya, Pranjal, et al.
Publicado: (2020)

KALRN mutations promote antitumor immunity and immunotherapy response in cancer
por: Li, Mengyuan, et al.
Publicado: (2020)

Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma
por: Liu, Fangming, et al.
Publicado: (2020)

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study
por: Bai, Xue, et al.
Publicado: (2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
por: Chardin, David, et al.
Publicado: (2020)

Galectin-9-based immune risk score model helps to predict relapse in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2020)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
por: Yao, Yao, et al.
Publicado: (2020)

Impact of body composition on outcomes from anti-PD1 +/− anti-CTLA-4 treatment in melanoma
por: Young, Arissa C, et al.
Publicado: (2020)

Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
por: Lu, Zhihao, et al.
Publicado: (2020)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes
por: Mazzotta, Marco, et al.
Publicado: (2020)

Is there a link between very early changes of primary and secondary lymphoid organs in (18)F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?
por: Seith, Ferdinand, et al.
Publicado: (2020)

Discovery and validation of surface N-glycoproteins in MM cell lines and patient samples uncovers immunotherapy targets
por: Oldham, Robyn A A, et al.
Publicado: (2020)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Stromal LAG-3(+) cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
por: Zeng, Han, et al.
Publicado: (2020)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma
por: Wang, Yuelong, et al.
Publicado: (2020)

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation
por: Cassetta, Luca, et al.
Publicado: (2020)

CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage
por: Zhu, Yanfang Peipei, et al.
Publicado: (2020)

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients
por: Xiong, Ying, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

LAG3 (LAG-3, CD223) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
por: Klümper, Niklas, et al.
Publicado: (2020)

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
por: Roelands, Jessica, et al.
Publicado: (2020)

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
por: Mitchell, Kyle G, et al.
Publicado: (2020)

Predictive value of integrated (18)F-FDG PET/MRI in the early response to nivolumab in patients with previously treated non-small cell lung cancer
por: Umeda, Yukihiro, et al.
Publicado: (2020)

Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer
por: Mo, Shaobo, et al.
Publicado: (2020)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
por: Ma, Huilin, et al.
Publicado: (2020)

Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy
por: Abed, Afaf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hqg9vc09effccqjqu3io1g80lo